phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutatio
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000001849
- Lead Sponsor
- agasaki Thoracic Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Pericardial effusion With subjective symptoms. Superior vena cava syndrome with necessary of emergecy radiation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival, overall survival, toxicity